Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study

December 2023 in “ Journal of Cosmetic Dermatology ”

Lingbo Bi, Chaofan Wang, Yimei Du, Tong Su, Zhao Min, Xuewen Lin, Weifei Fan, Weiyuan Sun

baricitinib JAK inhibitor alopecia areata Severity of Alopecia Tool SALT score platelet elevation elevated transaminase dizziness tonsillitis acne

From the encyclopedia

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study involved 32 patients with moderate to severe alopecia areata (AA) who were unresponsive to traditional treatments. These patients were treated with baricitinib, a JAK inhibitor, for 24 weeks. The results showed a significant decrease in the Severity of Alopecia Tool (SALT) score from baseline at week 12 and 24, indicating improved hair growth. By the end of the study, 68.75% of patients reported over 80% hair covering of the scalp. Side effects were mild and included transient platelet elevation, elevated transaminase, dizziness, tonsillitis, and acne. The study concluded that baricitinib is effective and safe for treating patients with refractory AA at moderate to severe levels.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

17 / 17 results

research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

1 citations , August 2023 in “JAMA Dermatology”

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

research Treatment of Moderate-to-Severe Alopecia Areata in Pre-Adolescent Children with Baricitinib

17 citations , April 2023 in “British Journal of Dermatology”

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , February 2023 in “American Journal of Clinical Dermatology”

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis

10 citations , January 2023 in “Acta dermato-venereologica”

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

$Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population$

research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population

2 citations , September 2022 in “Dermatologic Therapy”

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

$Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata$

research Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata

4 citations , September 2022 in “Dermatologic Therapy”

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Clinical Efficacy of Adipocyte-Derived Stem Cells Conditioned Media Combined with Micro-Injury in Refractory Patch of Alopecia Areata

14 citations , June 2021 in “Archives of Dermatological Research”

In this study, researchers evaluated the use of adipocyte-derived stem cell conditioned media combined with fractional laser or microneedling for treating refractory alopecia areata, finding that 64.3% of patients had significant hair regrowth, suggesting this combination may be an effective and safe treatment option.

research Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

67 citations , March 2021 in “Dermatology and Therapy”

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

research The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials

86 citations , January 2020 in “British Journal of Dermatology”

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , December 2018 in “Journal of autoimmunity”

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

research JAK-Inhibitors in Dermatology: Current Evidence and Future Applications

45 citations , November 2018 in “Journal of dermatological treatment”

This study reviewed 17 publications and found the strongest evidence supporting the efficacy of JAK-inhibitors in treating psoriasis, with some potential observed for alopecia areata, atopic dermatitis, and vitiligo, though further research is needed to compare with current treatments.

research Alopecia Areata: Treatment Options and Efficacy

182 citations , December 2017 in “Journal of the American Academy of Dermatology”

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

Alopecia Areata: Overview and Insights from January 2018